Absci to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Rhea-AI Summary

Absci Corporation (Nasdaq: ABSI) recently announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum scheduled for March 21, 2023, at 3:00 p.m. Eastern Time. This virtual event will feature a fireside chat with Absci management, providing insights into the company's innovative generative AI drug creation technologies.

Absci leverages AI alongside advanced wet lab methods to accelerate drug development, enhancing the probability of success by optimizing various drug characteristics. Interested parties can stream the event live via the company's investor relations website.

VANCOUVER, Wash. and NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming KeyBanc Capital Markets Life Sciences & MedTech Investor Forum.

Absci management is scheduled to participate in a fireside chat on Tuesday March 21^st at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.absci.com.

About Absci

Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), Twitter (@Abscibio), and YouTube.

Availability of Other Information about Absci

Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites, as well as on Twitter, LinkedIn and YouTube. The information that we post on these websites and social media outlets could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website and social media postings, or any other website that may be accessed from our website or social media postings, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Investor Contact
investors@absci.com

Media Contact
press@absci.com

 

FAQ

What date will Absci Corporation participate in the KeyBanc Capital Markets Investor Forum?

Absci Corporation will participate in the forum on March 21, 2023.

What time is Absci's management scheduled to speak at the investor forum?

Absci's management is scheduled to speak at 3:00 p.m. Eastern Time.

How can I access the live webcast of Absci's fireside chat?

The live webcast can be accessed through Absci's investor relations website.

What is Absci's focus in drug creation?

Absci focuses on generative AI drug creation to develop biologics more efficiently.

Where is Absci Corporation headquartered?

Absci Corporation is headquartered in Vancouver, Washington.